279 related articles for article (PubMed ID: 33541282)
41. Cyclin D1 and p21 in ulcerative colitis-related inflammation and epithelial neoplasia: a study of aberrant expression and underlying mechanisms.
Wong NA; Mayer NJ; Anderson CE; McKenzie HC; Morris RG; Diebold J; Mayr D; Brock IW; Royds JA; Gilmour HM; Harrison DJ
Hum Pathol; 2003 Jun; 34(6):580-8. PubMed ID: 12827612
[TBL] [Abstract][Full Text] [Related]
42. LGR5 is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines.
Walker F; Zhang HH; Odorizzi A; Burgess AW
PLoS One; 2011; 6(7):e22733. PubMed ID: 21829496
[TBL] [Abstract][Full Text] [Related]
43. Inverse correlation between PD-L1 expression and LGR5 expression in tumor budding of stage II/III colorectal cancer.
Sato K; Uehara T; Nakajima T; Iwaya M; Miyagawa Y; Watanabe T; Ota H
Ann Diagn Pathol; 2021 Jun; 52():151739. PubMed ID: 33862415
[TBL] [Abstract][Full Text] [Related]
44. The clinicopathological significance of Lgr5 expression in lung adenocarcinoma.
Ryuge S; Sato Y; Jiang SX; Wang G; Kobayashi M; Nagashio R; Katono K; Iyoda A; Satoh Y; Masuda N
Lung Cancer; 2013 Oct; 82(1):143-8. PubMed ID: 23915911
[TBL] [Abstract][Full Text] [Related]
45. Identification of novel Nrf2 target genes as prognostic biomarkers in colitis-associated colorectal cancer in Nrf2-deficient mice.
Hammad A; Zheng ZH; Gao Y; Namani A; Shi HF; Tang X
Life Sci; 2019 Dec; 238():116968. PubMed ID: 31628914
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer.
Valladares-Ayerbes M; Blanco-Calvo M; Reboredo M; Lorenzo-Patiño MJ; Iglesias-Díaz P; Haz M; Díaz-Prado S; Medina V; Santamarina I; Pértega S; Figueroa A; Antón-Aparicio LM
Int J Mol Sci; 2012; 13(4):4367-4387. PubMed ID: 22605983
[TBL] [Abstract][Full Text] [Related]
47. Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.
Yaeger R; Shah MA; Miller VA; Kelsen JR; Wang K; Heins ZJ; Ross JS; He Y; Sanford E; Yantiss RK; Balasubramanian S; Stephens PJ; Schultz N; Oren M; Tang L; Kelsen D
Gastroenterology; 2016 Aug; 151(2):278-287.e6. PubMed ID: 27063727
[TBL] [Abstract][Full Text] [Related]
48. Positive correlation of expression of L-type amino-acid transporter 1 with colorectal tumor progression and prognosis: Higher expression in sporadic colorectal tumors compared with ulcerative colitis-associated neoplasia.
Sakata T; Hana K; Mikami T; Yoshida T; Endou H; Okayasu I
Pathol Res Pract; 2020 Jun; 216(6):152972. PubMed ID: 32359697
[TBL] [Abstract][Full Text] [Related]
49. SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Gagné-Sansfaçon J; Coulombe G; Langlois MJ; Langlois A; Paquet M; Carrier J; Feng GS; Qu CK; Rivard N
Oncotarget; 2016 Oct; 7(40):65676-65695. PubMed ID: 27582544
[TBL] [Abstract][Full Text] [Related]
50. A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?
Mirzaei A; Tavoosidana G; Rad AA; Rezaei F; Tavakoli-Yaraki M; Kadijani AA; Khalili E; Madjd Z
Tumour Biol; 2016 Feb; 37(2):2405-14. PubMed ID: 26383518
[TBL] [Abstract][Full Text] [Related]
51. Characterization of LGR5 stem cells in colorectal adenomas and carcinomas.
Baker AM; Graham TA; Elia G; Wright NA; Rodriguez-Justo M
Sci Rep; 2015 Mar; 5():8654. PubMed ID: 25728748
[TBL] [Abstract][Full Text] [Related]
52. Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer.
Khare V; Dammann K; Asboth M; Krnjic A; Jambrich M; Gasche C
Inflamm Bowel Dis; 2015 Feb; 21(2):287-96. PubMed ID: 25569743
[TBL] [Abstract][Full Text] [Related]
53. The Expression Analysis of Intestinal Cancer Stem Cell Marker Lgr5 in Colorectal Cancer Patients and the Correlation with Histopathological Markers.
Salehzadeh S; Hasanzad M; Kadijani AA; Akbari A
J Gastrointest Cancer; 2020 Jun; 51(2):591-599. PubMed ID: 31422541
[TBL] [Abstract][Full Text] [Related]
54. Double Negativity for Expression of YAP1 and CDX2 Defines an Aggressive Type of Colitis-associated Cancer.
Yin F; Xie H; Lai J; Chen Y; Dong J; Zhang X; Liu X
Anticancer Res; 2020 Oct; 40(10):5411-5416. PubMed ID: 32988861
[TBL] [Abstract][Full Text] [Related]
55. Inactivation of JNK2 as carcinogenic factor in colitis-associated and sporadic colorectal carcinogenesis.
Lessel W; Silver A; Jechorek D; Guenther T; Roehl FW; Kalinski T; Roessner A; Poehlmann-Nitsche A
Carcinogenesis; 2017 May; 38(5):559-569. PubMed ID: 28383667
[TBL] [Abstract][Full Text] [Related]
56. LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma.
Ehara T; Uehara T; Nakajima T; Kinugawa Y; Kobayashi S; Iwaya M; Ota H; Soejima Y
BMC Cancer; 2021 Mar; 21(1):228. PubMed ID: 33676447
[TBL] [Abstract][Full Text] [Related]
57. Expression of the adult intestinal stem cell marker Lgr5 in the metastatic cascade of colorectal cancer.
Kleist B; Xu L; Li G; Kersten C
Int J Clin Exp Pathol; 2011 Apr; 4(4):327-35. PubMed ID: 21577318
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer.
Laurent C; Svrcek M; Flejou JF; Chenard MP; Duclos B; Freund JN; Reimund JM
Inflamm Bowel Dis; 2011 Jan; 17(1):232-40. PubMed ID: 20815042
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical analysis of HNF4A and β-catenin expression to predict low-grade dysplasia in the colitis-neoplastic sequence.
He Y; Chen L; Chen K; Sun Y
Acta Biochim Biophys Sin (Shanghai); 2021 Jan; 53(1):94-101. PubMed ID: 33300557
[TBL] [Abstract][Full Text] [Related]
60. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival.
Wu XS; Xi HQ; Chen L
World J Surg Oncol; 2012 Nov; 10():244. PubMed ID: 23153436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
